Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of intravenous bimagrumab in sporadic inclusion body myositis
2015-001411-12Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bimagrumab in inclusion body myositis (IBM) (4 arms), sponsored by Novartis. Primary endpoint: Safety and tolerability of different intravenous bimagrumab doses. Started Aug 2015; status: completed.
02
Drugs
bimagrumab
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on 2015-001411-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001411-12.